Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 1.00 |
| ▸ | CCR5 | P51681 | 2/20 | 1.00 |
| ▸ | CCR8 | P51685 | 2/20 | 1.00 |
| ▸ | NOS3 | P29474 | 2/20 | 0.61 |
| ▸ | NOS1 | P29475 | 2/20 | 0.61 |
| ▸ | NOS2 | P35228 | 2/20 | 0.61 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.47 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.47 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395249 | 1.00 | CCR1 (1.00) | CCR1CCR5CCR8NOS3NOS1 | |
| Methane SCHEMBL21386924 | 0.98 | CCR1 (0.95) | CCR1CCR5CCR8NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL29903189 | 0.98 | CCR1 (0.95) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL9135460 | 0.98 | CCR1 (0.95) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL28212407 | 0.98 | CCR1 (0.95) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL8746042 | 0.98 | CCR1 (0.95) | CCR1CCR5CCR8NOS3NOS1 | |
| Bromide SCHEMBL29619549 | 0.95 | CCR1 (0.91) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL30957052 | 0.91 | CCR1 (0.83) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL30656659 | 0.91 | CCR1 (0.83) | CCR1CCR5CCR8NOS3NOS1 | |
| SCHEMBL196913 | 0.91 | CCR1 (0.83) | CCR1CCR5CCR8NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1656 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12628491-B2 | Organic-inorganic adhesion layer and its use in perovskite solar cells and modules | Tandem PV (US) | 2026-05-12 | — | — | US | claimed |
| EP-4727953-A2 | ACCELERATED MARKING OF 5-FORMYL CYTOSINE AND USE IN NUCLEIC ACID METHYLATION SEQUENCING | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20250375458-A1 | COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES | THERALASE TECH INC (CA) | 2025-12-11 | — | — | US | claimed |
| US-20250375511-A1 | METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF INFECTIOUS AGENTS AND METAL CATIONS | THERALASE TECH INC (CA) | 2025-12-11 | — | — | US | claimed |
| US-20250362302-A1 | INTRACELLULAR LIGATION OF PHOTOCATALYSTS FOR PHOTO-RESPONSIVE, PROBE-MEDIATED PROTEIN LABELING | SEED THERAPEUTICS US INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20250114456-A1 | ENHANCED IMMUNOTHERAPEUTIC METHOD COMPRISING COMBINED ADMINISTRATION OF PHOTODYNAMIC / RADIOTHERAPEUTIC COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS | THERALASE TECHNOLOGIES, INC. (CA) | 2025-04-10 | — | — | US | claimed |
| WO-2025059098-A2 | PHOTOCATALYTIC CARBOXYLATION OF SUBSTRATES WITH CARBON OXIDE | NEW IRIDIUM INC. (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2025043152-A1 | METHODS OF DEALKENYLATIVE AMINATION AND AZIDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2024256358-A2 | ACCELERATED MARKING OF 5-FORMYL CYTOSINE AND USE IN NUCLEIC ACID METHYLATION SEQUENCING | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-19 | — | — | WO | claimed |
| WO-2024081751-A1 | ORGANIC-INORGANIC ADHESION LAYER AND ITS USE IN PEROVSKITE SOLAR CELLS AND MODULES | Tandem PV (US) | 2024-04-18 | — | — | WO | claimed |
| US-7479570-B2 | Process for reduction of carbon dioxide with organometallic complex | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-01-20 | — | — | US | claimed |
| US-20070036706-A1 | Catalytic reduction using a catalyst comprising an organometallic compound of cobalt, iron, iridium, osmium, rhodium, or ruthenium having a ligand such as 4,4'-dimethoxy-2, 2'-bipyridine; hydrogenation to formic acid or salt | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-02-15 | — | — | US | claimed |
| US-20030201194-A1 | Quantitative analysis; redox systems; monitoring glucose concentration | THERASENSE, INC. | 2003-10-30 | — | — | US | claimed |
| EP-0958495-B1 | SMALL VOLUME IN VITRO ANALYTE SENSOR | THERASENSE INC (US) | 2002-11-13 | — | — | EP | claimed |
| US-6120676-A | DETECTION AND QUANTIFICATION OF AN ANALYTE IN SUBMICROLITER SAMPLES. | THERASENSE, INC. (US) | 2000-09-19 | — | — | US | claimed |
| EP-0958495-A1 | SMALL VOLUME $i(IN VITRO) ANALYTE SENSOR | E. HELLER & COMPANY (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1998035225-A1 | SMALL VOLUME IN VITRO ANALYTE SENSOR | E. HELLER & COMPANY (US) | 1998-08-13 | — | — | WO | claimed |
| EP-0526603-B1 | Use of Mono, Bis or Tris (2,2'-substituted Bipyridine) complexes of a transition metal as mediators for current sensors | ASULAB SA (CH) | 1996-12-04 | — | — | EP | claimed |
| US-5393903-A | Mediator composition for coating an electrode of an amperometric sensor; for glucose testing in biological fluids | ASULAB S.A. (CH) | 1995-02-28 | — | — | US | claimed |
| US-5001268-A | Preparation of N-arylsubstituted amides | RHONE-POULENC CHIMIE (FR) | 1991-03-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375458-A1 | COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES | CD4, TPMT, SLC11A2 | CCR1 70/4885CCR5 119/4885CCR8 193/4885 |
| US-20250114456-A1 | ENHANCED IMMUNOTHERAPEUTIC METHOD COMPRISING COMBINED ADMINISTRATION OF PHOTODYNAMIC / RADIOTHERAPEUTIC COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS | PDCD1, CD47, CD274 | CCR1 471/4885CCR5 2069/4885CCR8 903/4885 |
| US-20250375511-A1 | METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF INFECTIOUS AGENTS AND METAL CATIONS | NFATC1, PCNA, PHPT1 | CCR1 2081/4885CCR5 3447/4885CCR8 3297/4885 |
| US-12628491-B2 | Organic-inorganic adhesion layer and its use in perovskite solar cells and modules | EPCAM, CDH1, L1CAM | CCR1 2140/4885CCR5 3549/4885CCR8 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.